CONMEDCNMD
CNMD
About: Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
Employees: 3,900
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
731% more call options, than puts
Call options by funds: $8.3M | Put options by funds: $999K
4.89% more ownership
Funds ownership: 111.15% [Q3] → 116.03% (+4.89%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
1% less capital invested
Capital invested by funds: $2.46B [Q3] → $2.45B (-$12.6M) [Q4]
1% less repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 97
7% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 42
3% less funds holding
Funds holding: 286 [Q3] → 276 (-10) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$70
19%
upside
Avg. target
$77
30%
upside
High target
$91
55%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Stifel Rick Wise 44% 1-year accuracy 15 / 34 met price target | 27%upside $75 | Buy Maintained | 6 Feb 2025 |
Wells Fargo Vik Chopra 42% 1-year accuracy 5 / 12 met price target | 19%upside $70 | Equal-Weight Maintained | 6 Feb 2025 |
Needham Mike Matson 39% 1-year accuracy 47 / 120 met price target | 55%upside $91 | Buy Maintained | 6 Feb 2025 |
JP Morgan Robbie Marcus 39% 1-year accuracy 7 / 18 met price target | 19%upside $70 | Neutral Downgraded | 6 Feb 2025 |
Financial journalist opinion
Based on 3 articles about CNMD published over the past 30 days
Neutral
Business Wire
2 weeks ago
CONMED Corporation Adds Mark Kaye to its Board of Directors
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. “My fellow directors and I are extremely pleased to welcome Mark to the board,” said Martha Goldberg Aronson, Chair of CONMED's Board of Directors. “Mark brings a wealth of experience to CONMED, including deep knowledge across finance, accounting, risk management, strategic planning, and operational efficiencies. He also brings a stro.
Neutral
Business Wire
2 weeks ago
CONMED Corporation Announces Quarterly Cash Dividend
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, includ.
Negative
Zacks Investment Research
3 weeks ago
New Strong Sell Stocks for February 19th
ACDVF, BN and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on February 19, 2024.
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for February 11th
ATS, CNMD and CSX have been added to the Zacks Rank #5 (Strong Sell) List on February 11, 2025.
Neutral
Zacks Investment Research
1 month ago
CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook
CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product.
Negative
Benzinga
1 month ago
These Analysts Slash Their Forecasts On Conmed After Q4 Results
CONMED Corporation CNMD posted better-than-expected earnings for its fourth quarter, but issued FY25 earnings and revenue guidance below estimates.
Positive
Zacks Investment Research
1 month ago
Here's What Key Metrics Tell Us About Conmed (CNMD) Q4 Earnings
Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Seeking Alpha
1 month ago
CONMED Corporation (CNMD) Q4 2024 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD ) Q4 2024 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Pat Beyer - Chief Executive Officer & President Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Rick Wise - Stifel Robbie Marcus - JPMorgan Vik Chopra - Wells Fargo Corporate & Investment Banking Young Li - Jefferies Travis Steed - BofA Securities Operator Thank you for standing by, and welcome to CONMED's Fourth Quarter Fiscal Year 2024 Earnings Conference Call. [Operator Instructions] Before the conference call begins, let me remind you that during this call, management will be making comments and statements regarding its financial outlook, its plans and objectives.
Positive
Zacks Investment Research
1 month ago
Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates
Conmed (CNMD) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.06 per share a year ago.
Neutral
Business Wire
1 month ago
CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Sales of $345.9 million increased 5.8% year over year as reported and 6.0% in constant currency. Domestic revenue increased 6.8% year over year. International revenue increased 4.4% year over year as reported and 5.0% in constant currency. Diluted net earnings per share (GAAP) were $1.08 compared to diluted n.
Charts implemented using Lightweight Charts™